Results 111 to 120 of about 76,815 (259)

Clinical outcomes of the chemo‐free approach in relapsed/refractory follicular lymphoma: A network meta‐analysis

British Journal of Haematology, EarlyView.
Graphical overview of the network meta‐analysis (NMA) evaluating chemo‐free approaches for relapsed/refractory follicular lymphoma (R/R FL). Epcoritamab plus rituximab (R2) achieved the highest cumulative ranking probability (SUCRA) across efficacy end‐points but increases the risk of predictable toxicity over anti‐CD20 monotherapy.
Daniele Caracciolo, Maria Rita Lombardo, Gianluca Reitano, Cristina Napoli, Lucia Fiorillo, Chiara Callerame, Mario Garritano, Alessio Bulotta, Maha Munir, Giulia Pensabene, Emiliano Barbieri, Alberto Bavieri, Pierfrancesco Tassone, Pierosandro Tagliaferri, Stefano Luminari   +14 more
wiley   +1 more source

Effects of chronic lymphocytic leukaemia (CLL)‐directed therapy on diffuse large B‐cell lymphoma (DLBCL) type Richter transformation compared to de novo DLBCL in a nationwide cohort

British Journal of Haematology, EarlyView.
Summary Diffuse large B‐cell lymphoma (DLBCL) type Richter transformation (DLBCL‐RT) in patients with chronic lymphocytic leukaemia (CLL) has a worse prognosis compared to de novo DLBCL (dnDLBCL). We investigated outcomes of patients with DLBCL‐RT with or without previous CLL‐directed therapy compared to dnDLBCL between 2002 and 2022.
Andreas Katsimigas, Mikkel Werling, Casper M. Frederiksen, Noomi Vainer, Klaus Rostgaard, Yasmin Ben‐Dali, Mariam H. Hleuhel, Christian Brieghel, Carsten U. Niemann, Caspar da Cunha‐Bang   +9 more
wiley   +1 more source

Correction: CAR-T cell therapy in non-Hodgkin lymphoma: a clinical trial landscape review. [PDF]

Front Immunol
Wu J, Liao Y, Wang W, Zhang X.
europepmc   +1 more source

A real‐world study on different initiation times and treatment durations of letermovir for cytomegalovirus prophylaxis after allogeneic haematopoietic stem cell transplantation

British Journal of Haematology, EarlyView.
Early letermovir initiation (day 0) after allogeneic haematopoietic stem cell transplantation (allo‐HSCT) reduced early cytomegalovirus (CMV) infection and delayed first CMV DNAemia compared with later starts. Extending prophylaxis to 200 days virtually eliminated late CMV reactivation and improved 1‐year overall survival, with no grade ≥3 drug‐related
Shiyu Chen, Zhihang Su, Xiaohan Zhang, Xiaoqing Li, Xin Du   +4 more
wiley   +1 more source

Pediatric Lymphoma in Jordan: A Retrospective Single-Center Study of Clinical Presentation, Treatment, and Outcomes. [PDF]

Cureus
Qatawneh MA, Altarawneh M, Alhwayan A, Alzghoul B, Altawarh A, Aljaafreh S, Alrawashdeh H, Abdalnabi A, AbuAli A, Khader M.   +9 more
europepmc   +1 more source

Integrating Flow Cytometry in the Diagnostic Work of HIV-Associated Hodgkin's Lymphomas. [PDF]

J Cell Mol Med
Santa M, Cenariu D, Tigu AB, Damian M, Rantshabeng P, Gaolathe T, Ndlovu AK, Abdelrahman K, Nistor M, Kegyes D, Gulei D, Jinca C, Bancos A, Rus I, Bumbea H, Tomacinschii V, Buruiana S, Bilal R, Selicean C, Zdrenghea M, Fetica B, Stefan C, Fromm J, Tomuleasa C.   +23 more
europepmc   +1 more source

Cancer Prevalence Among Large Cohort of Individuals With Down Syndrome: Implications for Screening Guidelines. [PDF]

Cancer Med
Fitzpatrick V, Noah A, Rivelli A, Johnson R, Zak M, Espinosa J, Chicoine B.   +6 more
europepmc   +1 more source

Prognostic impact of blood Epstein–Barr virus‐DNA in patients with peripheral T‐cell lymphoma, not otherwise specified

British Journal of Haematology, EarlyView.
Summary Peripheral T‐cell lymphoma, not otherwise specified (PTCL‐NOS), is a heterogeneous nodal T‐ and natural killer (NK)‐cell lymphoma with limited prognostic biomarkers. A subset of PTCL‐NOS characterized by Epstein–Barr virus (EBV) involvement in tumour cells has recently been recognized as EBV‐positive nodal T‐ and NK‐cell lymphoma (EBV+ nPTCL ...
Hyunseok Yoon, Hyungwoo Cho, In Hye Song, Sejin Kim, So Heun Lee, Kyoungmin Lee, Shin Kim, Chan‐Sik Park, Eun Jin Chae, Kyung Won Kim, Jin‐Sook Ryu, Sang‐Wook Lee, Jaewon Hyung, Heounjeong Go, Dok Hyun Yoon   +14 more
wiley   +1 more source

Incidence of Hodgkin and Non-Hodgkin Lymphomas: Comparison of the Military and General Population. [PDF]

Cancer Med
Robins KR, Bytnar JA, DeStefano CB, Shriver CD, Zhu K.   +4 more
europepmc   +1 more source

Covalent drug discovery: Progress against key targets, emerging strategies and lessons learnt

British Journal of Pharmacology, EarlyView.
Abstract Covalent drug discovery is currently experiencing a boom in industrial and academic interest. To date, at least 75 covalent drugs have received regulatory approval, targeting both traditional target classes and more challenging proteins for which other approaches failed. In many cases, unique aspects of covalent targeting are essential for the
Charles P. Brown, Alan Armstrong, David J. Mann   +2 more
wiley   +1 more source